Sigilon Therapeutics, Inc (SGTX)

Etorro trading 970x250
Sigilon Therapeutics, Inc (SGTX) Logo

About Sigilon Therapeutics, Inc

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. Address: 100 Binney Street, Cambridge, MA, United States, 02142

Sigilon Therapeutics, Inc News and around…

Latest news about Sigilon Therapeutics, Inc (SGTX) common stock and company :

10 Biggest Price Target Changes For Wednesday
01 Dec, 2021 FinancialContent

Morgan Stanley boosted Zscaler, Inc. (NASDAQ: ZS) price target from $275 to $330. Zscaler shares rose 7.1% to $371.50 in ...

Component Price Targets Imply 26% Gains Ahead For Russell 2000
30 Nov, 2021 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
30 Nov, 2021 FinancialContent

Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ:BOOM) from Neutral to Buy. In the ...

Sigilon Therapeutics Issues An Update On Its Early-Stage Hemophilia Study
29 Nov, 2021 FinancialContent

Sigilon Therapeutics Inc(NASDAQ: SGTX) reported that fibrosed spheres were observed during a retrieval procedure in a patient in ...

Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
29 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately severe hemophilia A. The SIG-001 trial had been placed on clinical hold by the FDA in July 2021 following Sigilon’s sub

Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
10 Nov, 2021 Yahoo! Finance

Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021 Company appoints May Orfali, M.D., M.B.A, as Chief Medical Officer CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therape

Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference
09 Nov, 2021 Yahoo! Finance

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the upcoming Jefferies London Healthcare Conference. The prerecorded fireside chat will we available on-demand starting Thursday, November 1

Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
29 Oct, 2021 FinancialContent

Upgrades For Preferred Bank (NASDAQ:PFBC), Stephens & Co. upgraded the previous rating of Equal-Weight to ...

Adding Up The Components: Russell 2000 Could Rise 20%
26 Oct, 2021 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change
13 Oct, 2021 Yahoo! Finance

Invaio Sciences, Inc., a Flagship Pioneering company unlocking the potential of natural systems to accelerate the transition to sustainable agriculture to urgently address climate change, has entered into a $50 million loan and security agreement with K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm.

How Bad Are Sigilon Therapeutics's Earnings? | Return On Capital Employed
22 Sep, 2021 FinancialContent

Benzinga Pro data, Sigilon Therapeutics (NASDAQ:SGTX) reported Q2 sales of $2.70 million. Earnings fell to a loss of $20.04 million, ...

Either Analysts Got The Components Wrong or Russell 2000 Headed 25% Higher
22 Sep, 2021 FinancialContent

The financial media loves to get predictions from experts about where they think a given stock market index is headed. Some experts look at technical analysis patterns, others look at valuation metrics, others apply a broad macro view of the economy..

Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
09 Sep, 2021 FinancialContent
72 Biggest Movers From Yesterday
08 Sep, 2021 FinancialContent

Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
07 Sep, 2021 FinancialContent

Gainers Surrozen (NASDAQ:SRZN) stock rose 33.14% to $9.64 during Tuesday's regular session. The company's market ...

Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
02 Sep, 2021 FinancialContent
Stocks That Hit 52-Week Lows On Friday
20 Aug, 2021 FinancialContent

On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) ...

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
19 Aug, 2021 FinancialContent

Thursday morning, 173 companies reached new 52-week lows. Areas of Interest: The largest company by market ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
17 Aug, 2021 FinancialContent

Tuesday morning, 282 companies set new 52-week lows. Key Facts: Alibaba Group Holding (NYSE:BABA) was the ...

Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
10 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
27 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Monday
26 Jul, 2021 FinancialContent

Monday morning saw 115 companies set new 52-week lows. Interesting Points: Alibaba Group Holding ...

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases
23 Jul, 2021 FinancialContent

Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases
23 Jul, 2021 Yahoo! Finance

Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical modelCAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported results from several ongoing preclinical studies in the

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
20 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Monday's After-Market Session
19 Jul, 2021 FinancialContent

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares moved upwards by 25.88% to $3.55 during Monday's after-market session. This ...

Sigilon Therapeutics, Inc (SGTX) is a NASDAQ Common Stock listed in , ,

970x250